Related Experiment Video
Updated: Mar 2, 2026
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
Cardiac stem cells: translation to human studies
Zijun Ge1,2, Sean Lal1,2,3, Thi Y L Le4,5
1Bosch Institute, The University of Sydney, Sydney, Australia.
Abstract:
The discovery of multiple classes of cardiac progenitor cells in the adult mammalian heart has generated hope for their use as a therapeutic in heart failure. However, successful results from animal models have not always yielded similar findings in human studies. Recent Phase I/II trials of c-Kit (SCIPIO) and cardiosphere-based (CADUCEUS) cardiac progenitor cells have demonstrated safety and some therapeutic efficacy. Gaps remain in our understanding of the origins, function and relationships between the different progenitor cell families, many of which are heterogeneous populations with overlapping definitions. Another challenge lies in the limitations of small animal models in replicating the human heart. Cryopreserved human cardiac tissue provides a readily available source of cardiac progenitor cells and may help address these questions. We review important findings and relative unknowns of the main classes of cardiac progenitor cells, highlighting differences between animal and human studies.
Insights
Cardiac progenitor cells offer heart failure therapy hope. While human trials show promise, understanding cell origins and improving animal models remain crucial for effective regenerative medicine.
Area of Science:
- Cardiology
- Regenerative Medicine
- Cell Biology
Background:
- Adult mammalian hearts contain multiple cardiac progenitor cell classes, sparking interest in heart failure therapies.
- Clinical trials (SCIPIO, CADUCEUS) using c-Kit and cardiosphere-derived cells show safety and some efficacy.
- Significant knowledge gaps exist regarding cardiac progenitor cell origins, functions, and interrelationships, compounded by population heterogeneity.
Purpose of the Study:
- To review current knowledge on cardiac progenitor cells for heart failure therapy.
- To highlight challenges in translating animal model findings to human studies.
- To discuss the potential of cryopreserved human cardiac tissue for advancing research.
Main Methods:
- Literature review of cardiac progenitor cell research.
- Analysis of findings from animal models and human clinical trials.
- Examination of challenges in cardiac progenitor cell characterization and application.
Main Results:
- Cardiac progenitor cell therapies demonstrate safety and potential efficacy in human trials.
- Discrepancies persist between animal model outcomes and human clinical results.
- Limitations in animal models hinder accurate replication of human cardiac conditions.
Conclusions:
- Further research is needed to clarify cardiac progenitor cell diversity and function.
- Bridging the gap between animal studies and human trials is essential for therapeutic success.
- Cryopreserved human cardiac tissue may offer a valuable resource for studying cardiac progenitor cells.
